The Future Of Treatment For Multiple Myeloma
In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest...
View ArticlePomalidomide Gets Positive Opinion From European Advisory Committee; Approval...
An advisory committee of the European Medicines Agency has issued a positive opinion regarding European approval of pomalidomide for the treatment of certain patients with multiple myeloma....
View ArticleASCO 2012 Multiple Myeloma Update – Day Three: Poster Presentations
This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday. Sunday started with a poster session in which...
View ArticleASCO 2013 Multiple Myeloma Update – Day Four: Oral Presentations
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago. Monday was the busiest day with regard to myeloma-related research. The day started...
View ArticleASCO 2013 And Multiple Myeloma: What Were The Highlights?
This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago. During the meeting, The Beacon published daily updates that provided overviews of the...
View ArticleThe European Hematology Association’s Annual Congress Starts Today: A Look At...
Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year. The first education and poster...
View ArticlePomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma
The European Commission (EC) has approved pomalidomide for the treatment of certain patients with multiple myeloma. The European brand name for the drug is expected to be “Imnovid,” although final...
View ArticleKyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?
A new retrospective study provides insight into the benefit the new myeloma drugs Kyprolis and Pomalyst may provide to patients who are resistant to, or cannot tolerate, both Velcade and Revlimid....
View ArticleResearchers Publish Final Results Of Pomalyst Trial That Led To Approval In...
Final results from a Phase 3 study show that Pomalyst in combination with low-dose dexamethasone is effective for relapsed and refractory multiple myeloma patients not responding to treatment with...
View ArticlePomalyst-Cyclophosphamide-Prednisone Combination Effective And Safe In...
Results from a recent Italian Phase 1/2 clinical trial indicate that the combination of Pomalyst, cyclophosphamide, and prednisone is effective and safe in relapsed and refractory multiple...
View Article